Journal Article Cites AlbuSorb™ for Serum Exosome Proteomic Analysis
MONMOUTH JUNCTION, NJ, May 14, 2018 -- Biotech Support Group reports on a recent journal article using
AlbuSorb™ to improve serum exosome purification for subsequent proteomic analysis.
The citation is:
Chettimada, Sukrutha, et al. "Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy." Scientific Reports 8.1 (2018): 7227.
The authors investigated the role that exosomes play in HIV pathogenesis, as little is known about exosome
cargo in relation to immune responses and oxidative stress. For this, plasma exosomes in HIV patients and
their relationship to immunological and oxidative stress markers were characterized by electron microscopy,
nanoparticle tracking, immunoblotting, and LC-MS/MS proteomics. For LC-MS/MS proteomics, the article
states “To obtain purified exosome fractions for proteomic analysis,… albuminwas depleted with 2 rounds of
albumin depletion using AlbuSorb™ - Albumin Depletion Kit (Biotech Support Group)”. Using untargeted
proteomic analysis, Exosomal Notch4 was increased in HIV-positive subjects versus controls and correlated
with immune activation markers. The results from this study suggest that exosomes in antiretroviral therapy-
treated HIV patients carry proteins related to immune activation and oxidative stress, have immunomodulatory
effects on myeloid cells, and may have pro-inflammatory andredox effects during pathogenesis.
“This reference shows that while exosomes are large hydrophobic vesicles, separating them from
surrounding protein content, can be difficult. Nevertheless, AlbuSorb™ is demonstrated here to be useful in
depleting albumin and enriching exosomes. Thus LC-MS/MS proteomic analysis of the exosomes is not
compromised by interference from serum albumin.” states Swapan Roy, Ph.D., President and Founder of
Biotech Support Group.
For more information visit: AlbuSorb at